The benzamide RH-5854 is shown to be highly potent toward tumor cells and to arrest nuclear division by a highly specific covalent binding to the b-subunit of tubulin in the colchicine binding region. Binding of 3 H-RH-5854 to b-tubulin in HCT-116 colon cancer cells is saturable and has been exploited in the development of a cell-based competitive binding assay, which allows antitubulin effects to be detected in whole cells. 3 H-RH-5854 binding is strongly inhibited by preincubating the cells with compounds that bind to the colchicine site and with paclitaxel. Binding of 3 H-RH-5854 is enhanced by preincubating the cells with vinblastine but not by other agents that bind at or near the vinblastine site (ansamitocin P-3 and phomopsin A). Various cytotoxic agents that do not act on tubulin do not affect binding of 3 H-RH-5854 in HCT-116 cells, demonstrating specificity of the assay for detection of antitubulin activity. As an alternative to traditional assays that employ isolated brain tubulin, the 3 H-RH-5854 binding assay enables screening for antitubulin effects directly in tumor cells, providing an assay that accounts for cell-specific criteria that influence sensitivity such as different tubulin isotypes, tubulin mutations, drug metabolism, and efflux mechanisms. (Journal of Biomolecular Screening 2006:82-89) 
INTRODUCTION
A WIDE VARIETY OF NATURAL AND SYNTHETIC compounds prevent nuclear division by binding to tubulin and disrupting cellular microtubules. [1] [2] [3] Such compounds have attracted particular interest as anticancer agents due to their ability to arrest cell division, as well as to the successful clinical use of paclitaxel, and the Vinca alkaloids vinblastine and vincristine. 4 Antitubulin compounds have also been widely used in agriculture as herbicides and fungicides. 5 Zoxamide (Fig. 1) is a benzamide that has been commercialized as an agricultural fungicide to control diseases caused by Oomycete fungi on vines and vegetables. 6 RH-4032, a close structural analog of zoxamide, is especially potent toward plant cells. 7 Both RH-4032 and zoxamide comprise 2 enantiomers, but their biological activity results primarily from activity of the S-enantiomer (unpublished results). These benzamides have been shown to bind covalently to the bsubunit of tubulin when applied to whole cells or to isolated bovine tubulin, 7, 8 and this property has enabled their use as radioligands in cell-based binding assays to detect antitubulin activity in tobacco 7 and the Oomycete fungus Phytophthora capsici. 8 Tubulin can be isolated readily from brain tissue in large quantity but only with difficulty from many other cell types. For this reason, isolated brain tubulin is generally used in mechanismbased assays to detect antitubulin chemistries. Such assays typically measure effects on the in vitro assembly of microtubules or binding of radiolabeled antitubulin compounds to tubulin. 1, 2 However, different tumor cells can vary greatly in their sensitivity to antitubulin drugs due to the presence of different isotypes of tubulin, 9, 10 efflux mechanisms, 10 and tubulin mutations. 11 In the present study, we show that RH-5854 ( Fig. 1) , a benzamide with high potency toward tumor cells, can be used as a radioligand in a cell-based competitive binding assay to detect antitubulin activity. This approach can be used to screen for antitubulin compounds directly in a tumor cell line of interest, thus accounting for cell-specific parameters that affect sensitivity.
MATERIALS AND METHODS

Materials
In all experiments, the RH-5854 sample used was the Senantiomer, unless otherwise noted. RH-4032 and zoxamide were racemic mixtures. 3 H-RH-5854 (18 Ci/mmol) was prepared by tritium gas exchange and was stored at -20°C in toluene. For experi-ments, aliquots of the toluene stock were evaporated to dryness and redissolved in DMSO. Paclitaxel was obtained from Calbiochem (San Diego, CA). Vinblastine, colchicine, podophyllotoxin, nocodazole, chlorambucil, cis-platinum, mitomycin C, camptothecin, daunorubicin, etoposide, 5fluorouracil, acivicin, amethopterin, 5¢-aza-2¢-deoxycytidine, and hydroxyurea were from Sigma (St. Louis, MO). Ansamitocin P-3, dolastatin 15, phomopsin A, TN-16, tubulozole-C, and tubulozole-T were from Biomol (Plymouth Meeting, PA).
Cell lines
The human colon cancer cell line HCT-116 was obtained from the American Type Culture Collection (Manassas, VA) and was cultured in McCoy's 5A medium containing 2 mM L-glutamine, 10% fetal bovine serum, 50 units of penicillin/mL, and 50 mg of streptomycin/mL. Media components were obtained from Life Technologies (Rockville, MD). The human lymphoblastic leukemia cell lines CCRF-CEM and CCRF-CEM/VBL 100 12 were obtained from W. T. Beck (University of Illinois, Chicago) and were grown in SMEM medium (BioWhittaker, Walkersville, MD) containing 2 mM L-glutamine and 10% fetal bovine serum.
Chromosome staining
HCT-116 cells were treated with RH-5854 for 7 h and stained with aceto-orcein, as described previously. 13 Mitotic indices (percentage of cells in arrested metaphase) were determined based on examination of 200 cells per treatment.
In vitro microtubule assembly
Tubulin was isolated from bovine brain by 2 cycles of assembly/disassembly. 14 Inhibition of microtubule assembly was assayed turbidimetrically as described previously. 7 3 
Labeling of isolated bovine tubulin with
H-RH-5854 and analysis of radiolabeled protein
Tubulin (10 mM) in 1.0 M sodium glutamate, pH 6.6, containing 1 mM MgCl 2 was incubated with 2 mM 3 H-RH-5854 (specific activity 2.98 Ci/mmol) for 1 h at 37°C, then cooled on ice and the tubulin precipitated by addition of 20% trichloroacetic acid and incubation on ice for a further 20 min. After centrifugation at 12,000g for 5 min, the tubulin pellet was washed with 80% icecold acetone, dissolved in SDS-PAGE sample buffer (62 mM Tris-HCl buffer, pH 6.8, containing 3% sodium dodecyl sulfate, 5% mercaptoethanol, and 10% glycerol), heated for 2 min at 100°C, and then subjected to SDS-PAGE on a 7.5% polyacrylamide gel. 15 The gel was stained with Coomassie brilliant blue R250, impregnated with EN 3 HANCE (NEN Life Science Products), dried, and analyzed by autoradiography using Kodak X-OMAT AR film.
Analysis of radiolabeled protein after labeling of HCT-116 cells with 3
H-RH-5854
Cell suspension (1 mL at 10 6 cells/mL) in serum-free medium was incubated with 0.1 mM 3 H-RH-5854 (specific activity 18 Ci/ mmol) for 1 h at 37°C with gentle shaking, and then 50 mM unlabeled RH-5854 was added to stop the reaction. Cells were washed twice with serum-free medium by centrifugation, lysed by resuspending in 100 mL of M-Per reagent (Pierce Chemical Co., Rockford, IL) containing 0.1 mM phenylmethylsulfonyl fluoride, and shaken gently for 10 min. After centrifugation at 27,000g for 15 min at 4°C, the supernatant was recovered and analyzed by SDS-PAGE. In experiments to determine the effect of other antitubulin agents on binding of 3 H-RH-5854, the cells were preincubated with the antitubulin agent for 1 h at 37°C before addition of the radioligand.
HCT-116 cell-binding assay
The following procedure was developed to measure the effect of antitubulin compounds on the rate of binding of 3 H-RH-5854. HCT-116 cells were harvested from culture flasks by trypsinization and diluted with incomplete medium (McCoy's 5A medium containing 2 mM L-glutamine) to a density of 10 6 /mL. The assays were performed in 96-well MultiScreen glass fiber harvest plates (Millipore, Bedford, MA), and washing and filtration steps were carried out using a MultiScreen vacuum manifold (Millipore). Wells were prewetted by addition of 100 mL of incomplete medium, followed by removal of the liquid under vacuum. The underside of the plates was blotted dry and sealed with adhesive backing tape, and then cell suspension (150 mL) was added to the wells. Cells were preincubated with test compounds before adding the radioligand by adding 25 mL of compound as a solution in incomplete medium containing 12% DMSO. The DMSO was used to solubilize the test compounds and did not affect the binding results at the concentration used. To determine nonspecific bind- ing, cells were preincubated with unlabeled RH-5854 at a concentration of 50 mM based on experiments that showed that a concentration > 25 mM was needed to minimize values for nonspecific binding. Plates were placed on a rotary shaker for 2 to 3 min to mix the contents and then incubated at 37°C for 1 h. 3 H-RH-5854 was added to the wells as 25 mL of a 7.7-mM solution in incomplete medium containing 1% DMSO, and the plates were incubated at 37°C for 1 h. Preliminary experiments showed that binding of 3 H-RH-5854 increased linearly during this period so that the level of specific binding at 1 h represents the rate of radioligand binding. The adhesive film was removed from the base of the plate, the liquid was removed by filtration, and the wells were washed 5 times with 250 mL of ice-cold ethanol. After drying at 37°C for 20 min, 100 mL of Microscint 20 scintillation fluid (Packard Instrument Co., Meriden, CT) was added to the wells and radioactivity measured in a TopCount NXT microplate scintillation counter (Packard).
Cytotoxicity assay
Cytotoxicity toward HCT-116, CCRF-CEM, and CCRF-CEM/ VBL 100 cells was measured in 96-well microplates using a sulforhodamine B assay. 16 Compounds were tested at a series of 2fold dilutions with 4 replicates at each concentration. Cytotoxicity toward the mouse lymphoma cell line L5178Y was determined by cell counting of treated cultures as described previously, 13 using a series of 4-fold dilutions of test compound and 2 replicates at each concentration.
Localization of the benzamide binding site
Isolated bovine tubulin (10 mM) in 1.0 M sodium glutamate, pH 6.6, containing 1 mM MgCl 2 was incubated with 50 mM RH-4032 in a 25-mL reaction volume for 6 h at 37°C. To remove unincorporated RH-4032, the tubulin was precipitated with ice-cold acetone and centrifuged to pellet the protein. The pellet was washed with 80% acetone and dissolved in 25 mL of 8 M urea containing 0.4 M NH 4 HCO 3 . The tubulin was reduced by addition of 4 mM dithiothreitol and incubation at 50°C for 15 min, then alkylated by reaction with 16.7 mM iodoacetic acid for 15 min. The tubulin was digested with sequencing-grade trypsin (Promega, Madison, WI) at a ratio of 1:100 (w/w) for 26 h at 37°C, dialyzed against 0.1 M NH 4 HCO 3 , and lyophilized. For mass spectroscopy, samples were diluted in a matrix of a-cyano-4-hydroxycinnamic acid. Spectra were acquired on a Bruker Reflex MALDI-TOF mass spectrometer operating in reflector mode with an acceleration voltage of 30 kV.
RESULTS
Inhibition of tumor cell growth and microtubule assembly
In testing against the colon cancer cell line HCT-116 and the mouse lymphoma cell line L5178Y, RH-5854 ( Fig. 1) was found to be a much more potent inhibitor of cell growth than the previously described benzamides RH-4032 and zoxamide ( Table 1) . RH-5854 was also highly active toward the multi-drug-resistant (MDR) cell line CCRF-CEM/VBL 100 , which is resistant to paclitaxel and vinblastine, and showed comparable potency toward its drug-sensitive parental cell line CCRF-CEM ( Table 2) . Chromosome staining of cells treated with RH-5854 revealed an increase in the mitotic index similar to that of the antitubulin agent colchicine due to an accumulation of cells in arrested metaphase ( Table 3) . Consistent with this indication of possible antitubulin activity, RH-5854 strongly inhibited the in vitro assembly of bovine microtubules (Fig. 2) . As found for other benzamides, 7, 8 strong inhibition of microtubule assembly by RH-5854 was dependent on preincubation of the inhibitor with tubulin prior to initiation of assembly, as shown in Figure 2 by the stronger inhibition of assembly following 6-h preincubation than with a 1-h preincubation.
Covalent binding to b-tubulin
Previous studies showed that RH-4032 and zoxamide bind covalently with high specificity to b-tubulin when added to plant and fungal cells or to isolated tubulin. 7, 8 Similarly, when isolated bovine tubulin was treated with 3 H-RH-5854, analysis of radiolabeled protein by SDS-PAGE and autoradiography indicated covalent labeling of the b-subunit and no binding to a-tubulin (Fig. 3A,B) . Labeling of HCT-116 cells with 3 H-RH-5854 also revealed highly specific labeling of a single protein that comigrated with bovine brain b-tubulin ( Fig. 3C,D) .
To localize the covalent site of benzamide binding on tubulin, tryptic digests of RH-4032-labeled tubulin and unlabeled tubulin were analyzed by MALDI-mass spectroscopy to search for molecular weight shifts of individual peptides. The spectrum for the digest of RH-4032-labeled tubulin was found to differ from that of the unlabeled sample in the disappearance of a molecular ion of m/ z 2710, corresponding closely to the expected mass (2709 Da) of the peptide corresponding to residues 217 to 241 of b-tubulin (alkylated by iodoacetic acid), and the appearance of a new ion of m/z 2939, corresponding closely to the expected mass (2937 Da) of the same peptide alkylated with RH-4032 through reaction with the a-chloroketone moiety.
Competitive binding assay in HCT-116 cells and effects of antitubulin and cytotoxic agents
Specific binding of 3 H-RH-5854 to HCT-116 cells was found to be saturable as a function of radioligand concentration (Fig. 4A) , with half-maximal binding at 9.9 mM. Scatchard analysis of the specific binding data produced a linear plot (Fig. 4B) consistent with a single set of binding sites. Binding of 3 H-RH-5854 in HCT-116 cells was strongly inhibited by paclitaxel with 50% inhibition of binding at approximately 3 nM (Fig. 5A) , a value that is comparable to its EC 50 value for cytotoxicity of 1.5 nM ( Table 4) .
Cell-Based
Compounds that are believed to bind to the colchicine site on tubulin (colchicine, podophyllotoxin, nocodazole, TN-16, and tubulozole C) all inhibited binding of 3 H-RH-5854. However, the concentrations required to inhibit 3 H-RH-5854 binding were considerably higher than corresponding EC 50 values for cytotoxicity ( Table 4 ). Tubulozole T, the biologically inactive isomer, had little effect on 3 H-RH-5854 binding.
Vinblastine was found to increase binding of 3 H-RH-5854 in HCT-116 cells (Fig. 5B) . In contrast, ansamitocin P-3 and phomopsin A, which are believed to bind near the vinblastine site, had little effect on binding ( Table 4 ).
The effects of paclitaxel, podophyllotoxin, and vinblastine on the binding of 3 H-RH-5854 to b-tubulin in HCT-116 cells were also analyzed by SDS-PAGE of whole-cell extracts and autoradiography to confirm that the inhibition or enhancement of radioligand binding reflected binding to b-tubulin. In agreement with the binding assay results, paclitaxel and podophyllotoxin inhibited binding to b-tubulin, whereas vinblastine enhanced binding ( Fig. 6) .
A number of cytotoxic agents that act by general alkylation, inhibition of topoisomerases, or inhibition of nucleic acid synthesis were evaluated in the assay. None of these agents showed significant effects on binding of 3 H-RH-5854 ( Table 5 ), suggesting that the assay is highly specific for detection of antitubulin activity.
DISCUSSION
RH-5854 was more potent than RH-4032 and zoxamide toward tumor cells ( Table 1) , but it is > 90-fold less active toward tobacco suspension cultured cells than RH-4032 (unpublished results) and > 13-fold less active than zoxamide toward the Oomycete fungus P. capsici. 8 Although RH-5854 differs from these benzamides in H-RH-5854 in the HCT-116 cell binding assay. Cells were incubated with paclitaxel or vinblastine at the appropriate concentrations for 1 h, then with its relative potency toward different organisms, it was found to act by the same mechanism as other benzamides, involving the arrest of nuclear division due to a highly specific covalent binding to btubulin. Based on its antitubulin mode of action and high potency, RH-5854 was selected as the most suitable ligand for developing a tubulin binding assay in tumor cells.
The binding assay we have developed in HCT-116 cells using 3 H-RH-5854 is highly specific for detection of certain classes of antitubulin compounds and is not sensitive to a variety of cytotoxic agents that act by other mechanisms. Inhibitors of microtubule assembly have been assigned to 2 broad classes based on binding to either the colchicine site or the vinblastine site, both of which are generally believed to reside on the b-tubulin subunit. 1, 2, 17 In addition to colchicine, compounds employed in the present study that have been proposed to bind to the colchicine site include podophyllotoxin, 1 TN-16, 18 the benzimidazole analog nocodazole, 1 and tubulozole C. 19 These ligands all inhibited binding of 3 H-RH-5854, suggesting that RH-5854 may bind near the colchicine site on b-tubulin. For most of the colchicine site ligands, their ranking according to inhibitory activity in the binding assay agrees well with their cytotoxicity, the order of potency in both being podophyllotoxin > colchicine > TN-16 > tubulozole C. Nocodazole was less active than TN-16 and tubulozole C in the binding assay despite showing higher cytotoxicity. The reason for the lower activity of nocodazole in the binding assay relative to other colchicine site ligands is not clear. This result may indicate a difference between nocodazole and the other colchicine site ligands in its binding kinetics, location of its binding site, or conformational effects on tubulin.
IC 50 values for inhibition of 3 H-RH-5854 binding by the colchicine site ligands are significantly higher than corresponding EC 50 values for cytotoxicity. Analyzing such differences between binding assay IC 50 values and cytotoxicity values is complicated by the fact that 3 H-RH-5854 binds covalently because the competing ligand and radioligand are not in a state of binding equilibrium at the time of measurement. However, for colchicine site ligands, a major reason for these differences is probably their ability to inhibit microtubule assembly at substoichiometric concentrations if they act by a "tip-poisoning" mechanism, as has been proposed for colchicine. 20 2,4-Dichlorobenzyl thiocyanate (DCBT) and the antitumor sulfonamidobenzene compound T138067 are known to bind covalently to tubulin when applied to intact cells, 21, 22 and both compounds are reported to bind to cys-239 in b-tubulin. 22, 23 Our finding that RH-4032 binds to a peptide corresponding to residues 217 to 241 of b-tubulin, which contains a single cysteine at position 239, suggests a common site of covalent attachment for the benzamides, DCBT and T138067. Studies of the effects of antitubulin agents on binding of these ligands also support this conclusion. Similar to our results for RH-5854, binding of T138067 was inhibited by colchicine and paclitaxel but enhanced by vinblastine, 22 and binding of DCBT to tubulin was shown to be inhibited by colchicine. 21 Consistent with the involvement of cys-239 in covalent binding of these ligands and inhibition of binding by colchicine, the proximity of cys-239 to the colchicine site was proposed earlier based on the ability of colchicine to inhibit reaction of this residue with thiol cross-linking reagents. 24 Three compounds that bind at or near the vinblastine site 2vinblastine, ansamitocin P-3, and phomopsin A-were tested for their effects on binding of 3 H-RH-5854 in HCT-116 cells. Because none of these compounds inhibited 3 H-RH-5854 binding, it is clear that the benzamide does not bind to the vinblastine site. Whereas ansamitocin P-3 and phomopsin A had little effect on 3 H-RH-5854 binding, vinblastine increased binding of 3 H-RH-5854 dramatically. The differential effect of vinblastine as compared with ansamitocin P-3 and phomopsin A presumably reflects conformational changes in tubulin, which are induced by vinblastine but not by the other ligands. The interaction of vinblastine with tubulin is known to induce various changes in tubulin, which suggest conformational change such as stabilization of the colchicine binding activity, a reduction in the rate at which bis(8-anilinonaphthalene-1-sulfonate) interacts with hydrophobic regions of the protein, changes in the reaction of tubulin with alkylating agents, and the induction of an aberrant polymerization of tubulin. 2 Although ansamitocin P-3 and phomopsin A inhibit binding of vinblastine to tubulin, they differ from vinblastine with respect to other effects on tubulin, and these findings have been interpreted in terms of a model in which the binding domains of the various ligands do not overlap completely. 2 The cytotoxicity EC 50 value for vinblastine toward HCT-116 cells was 0.9 nM, and at a similar concentration (1 nM), vinblastine has been shown to inhibit mitosis in HeLa cells, apparently by inhibiting both the addition and loss of tubulin at the growing ends of microtubules without causing appreciable depolymerization. 25 At much higher concentrations (> 1 mM), vinblastine causes depolymerization of microtubules by inducing peeling of protofilaments at both microtubule ends. 1 In our experiments, the increase in 3 H-RH-5854 binding in HCT-116 cells occurred at comparable high concentrations ( Fig. 5B ), suggesting that a conformational change associated with this depolymerization process could be responsible for enhanced 3 H-RH-5854 binding.
Binding of 3 H-RH-5854 in HCT-116 cells was very sensitive to inhibition by the anticancer drug paclitaxel, which promotes microtubule assembly by binding to a different region from colchicine on b-tubulin. 17 In contrast to results for colchicine site ligands, the IC 50 for inhibition of 3 H-RH-5854 binding by paclitaxel (3 nM) and its cytotoxicity EC 50 value (1.5 nM) are comparable. Previous studies have shown that paclitaxel also inhibits binding of benzamides to b-tubulin in tobacco 7 and in the Oomycete fungus P. capsici (unpublished results). As discussed previously, 7 a likely explanation for inhibition of 3 H-RH-5854 binding by paclitaxel is that benzamides bind to the disassembled form of tubulin and that paclitaxel reduces the cellular concentration of free tubulin available for binding of the radioligand by virtue of its ability to promote microtubule assembly. From in vitro studies, it is known that paclitaxel suppresses microtubule dynam-ics at substoichiometric concentrations and that its effect differs depending on the stoichiometry of binding. 26 As a result, paclitaxel affects the relative amounts of free and polymerized tubulin in a complex biphasic manner over a concentration range spanning several orders of magnitude. 26 The fact that the dose-response curve for inhibition of 3 H-RH5854 binding by paclitaxel ( Fig. 5A) was also characterized by a relatively shallow slope, or low Hill coefficient, appears consistent with our hypothesis that the reduction in 3 H-RH5854 binding results from a lower concentration of free tubulin. If this explanation is correct, 3 H-RH-5854 binding should be sensitive to other agents that promote microtubule assembly regardless of their binding site. This suggests a broad utility of the assay in screening for new compounds that promote microtubule assembly.
Competitive binding assays using benzamide probes provide a new approach for studying antitubulin effects in a variety of organisms. A serious problem in the study of antitubulin compounds has been the reliance on in vitro experiments using brain tubulin, necessitated by the difficulty in isolating sufficient tubulin from other cell types. In the case of mammalian tumor cells, different cell types may differ greatly in sensitivity to a given antitubulin compound because of to a variety of factors such as differences in the expression and sensitivity of tubulin isotypes, tubulin mutations and differences in uptake, metabolism, or efflux of the compound. The assay method we have developed for HCT-116 cells is probably applicable to many other mammalian cell lines. Sensitivity of the MDR cell line CCRF-CEM/VBL 100 to RH-5854 also suggests that competitive binding assays could be developed in certain MDR cells. An attractive feature of the 3 H-RH-5854 binding assay is the potential to test antitubulin effects directly in a cell line of interest so that differences in tubulin composition and cellular uptake, efflux, or metabolism of the compound are taken into account.
